ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Revolade®:Novartis Pharma Schweiz AG
Vollst. FachinformationDDDDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
B02BX05 - EltrombopagATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
 
B02 - Antihemorrhagics
 
B02B - Vitamin K and Other Hemostatics
 

The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).

B02BX - Other Systemic Hemostatics

This group comprises systemic hemostatics, which cannot be classified elsewhere.

The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.

B02BX05 - Eltrombopag
StärkeAdm.RouteNote
 O 
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home